Skip to main content
VVOS logo

Vivos Therapeutics, Inc. (VVOS) Stock: Price, Forecast & Analyst Target

Vivos Therapeutics, Inc. (VVOS) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $0.0569 (-25.13%), as of the Nov 19, 2026 trading session; market cap $1.92M.

Educational signal · not a buy or sell recommendation · How to read this

$0.0569 −$0.0191 (-25.13%) Market Cap $1.92M

Vivos Therapeutics, Inc. · VVOS

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing non-invasive treatments for dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring. The company's core offering is The Vivos Method, a multi-disciplinary treatment modality marketed to general dentists.

Price as of Nov 19, 2026

Key Statistics

19 of 100

MoonshotScore v2 · Vivos Therapeutics (VVOS)

Weak
Business Quality Thin (33)
Financial Safety Fragile (1)
Valuation Rich (31)
Growth Durability Fading (23)
Momentum Falling (14)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

Weak quality, a fragile balance sheet, stalling growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Fragile; Valuation: Rich; Growth Durability: Fading; Momentum: Falling.

  • quarterly revenue $5M (Q2 FY2026, quarter ended Jun 30, 2026)
  • EPS beat 4 of the last 8 reports
  • Altman Z -11.38 · Piotroski F 2

Holding back: weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for VVOS (57 recorded, newest six shown)
RecordedScoreBand
20Weak
20Weak
20Weak
20Weak
19Weak
19Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0569
Change on the day-25.13%
52-week range$0.0569 – $2.69
Market capitalisation$1.92M—
Shares traded on the day4.38M

Price & events

Other perspectives

Council score for Vivos Therapeutics (VVOS): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Weak
Financial Safety Negative
Valuation Weak
Growth Durability Weak
Momentum Negative

Legends Council

3 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Oct 8, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Moderate
Debt/Equity Strong
ROE Strong
Gross Margin Moderate

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Vivos Therapeutics (VVOS), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Vivos Therapeutics, Inc. (VVOS) is the company analyzed here. It employs 268 people and is led by R. Kirk Huntsman. In Q2 FY2026 it reported revenue of $5M and net income of -$5M. The market values it at $1.92M.

2 · Latest results

What do the latest results show for Vivos Therapeutics (VVOS)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of $5M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026$5M-$5M-$0.31 (diluted)
Q1 FY2026$5M-$8M-$0.52 (diluted)
Q4 FY2025$4M-$7M-$0.74 (diluted)
Q3 FY2025$7M-$5M-$0.49 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Vivos Therapeutics (VVOS)?

Short answer · as of

What is holding it back is weak fundamentals, balance-sheet strain, a rich price, soft growth, weak price trend. The distress and quality screens read Altman Z -11.38 · Piotroski F 2. Trailing ratios: current ratio 0.21.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of -11.38 sits in the distress zone (elevated bankruptcy risk).
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at Vivos Therapeutics (VVOS)?

Short answer · as of

Current published price targets run low $1.75 · high $2.50 · consensus $2.13 · median $2.13 against a quoted price of $0.0569 (as of Nov 19, 2026).

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Vivos Therapeutics compare with its peers?

Short answer

Vivos Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
ResMed Inc. (RMD) Named competitor$242.61 Nov 18, 2026$34.1B95 5-pillar Nov 18, 2026
Viemed Healthcare, Inc. (VMD) Same industry, near in market value$8.78 Nov 18, 2026$333M88 5-pillar Nov 18, 2026
Electromed, Inc. (ELMD) Same industry, near in market value$23.40 Nov 18, 2026$191M87 5-pillar Nov 18, 2026
Align Technology, Inc. (ALGN) Named competitor$163.96 Nov 18, 2026$11.6B83 5-pillar Nov 18, 2026
Anika Therapeutics, Inc. (ANIK) Same industry, near in market value$13.62 Nov 18, 2026$182M71 5-pillar Nov 18, 2026
LENSAR, Inc. (LNSR) Same industry, near in market value$4.85 Nov 18, 2026$59.6M44 5-pillar Nov 18, 2026
Solana Company (HSDT) Same industry, near in market value$1.63 Nov 18, 2026$103M43 5-pillar Nov 18, 2026
Owlet, Inc. (OWLT) Same industry, near in market value$3.67 Nov 18, 2026$110M41 5-pillar Nov 18, 2026
Hyperion DeFi, Inc. (HYPD) Same industry, near in market value$2.38 Nov 18, 2026$36.2M39 5-pillar Nov 18, 2026
Inogen, Inc. (INGN) Same industry, near in market value$5.57 Nov 18, 2026$145M37 5-pillar Nov 18, 2026
Orthofix Medical Inc. (OFIX) Same industry, near in market value$6.61 Nov 18, 2026$269M36 5-pillar Nov 18, 2026
Apyx Medical Corporation (APYX) Same industry, near in market value$2.49 Nov 18, 2026$105M33 5-pillar Nov 18, 2026
Vivos Therapeutics (VVOS) — this page$0.0569$1.92M19

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$1.75 – $2.50
Consensus target
$2.13
Median target
$2.13

Consensus record · Captured .

Measured against a quoted price of $0.0569 (as of Nov 19, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held VVOS in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported VVOS in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Vivos Therapeutics (VVOS)?

Read these with our analysis →

Investor Questions: VVOS Stock

These answers are editorial: 2 of these 9 answers are drawn from the VVOS research dossier (written Mar 16, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for VVOS?

VVOS carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is VVOS a good stock to buy?

Stock Expert AI does not rate VVOS buy, sell or hold. Vivos Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the VVOS stock price today?

The last price recorded for Vivos Therapeutics, Inc. (VVOS), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the VVOS price target?

The analyst consensus price target for Vivos Therapeutics, Inc. (VVOS), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for VVOS?

The main risks for Vivos Therapeutics, Inc. include its negative profitability and high debt levels, which pose a significant financial risk. Competition from established players in the sleep apnea market, such as ResMed and Align Technology, could limit market share.

What are the key growth opportunities for VVOS in healthcare?

Vivos Therapeutics, Inc. has several key growth opportunities within the healthcare sector.

What are the key factors to evaluate for VVOS?

Vivos Therapeutics, Inc. (VVOS) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. By increasing the number of trained providers, Vivos can reach a wider patient population and drive revenue growth. Not financial advice.

How frequently does VVOS data refresh on this page?

VVOS's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven VVOS's recent stock price performance?

Vivos Therapeutics, Inc. (VVOS) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary Vivos Method with patent protection. See the News tab for the latest drivers. Past performance does not predict future results.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.